oxybutynin has been researched along with Heart Failure in 4 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "TY-0201 (TY) is a transdermal formulation of bisoprolol that is the free base of bisoprolol fumarate (BO), a drug widely used to treat chronic heart failure (CHF)." | 9.24 | Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure. ( Daimon, M; Dohi, N; Kinugawa, K; Komuro, I; Momomura, SI; Okamoto, H; Saito, Y; Sakata, Y; Yamamoto, K; Yasumura, Y, 2017) |
| "However, orthostatic hypotension (OH) is sometimes caused by BBs." | 5.56 | Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T; Sano, T, 2020) |
| "TY-0201 (TY) is a transdermal formulation of bisoprolol that is the free base of bisoprolol fumarate (BO), a drug widely used to treat chronic heart failure (CHF)." | 5.24 | Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure. ( Daimon, M; Dohi, N; Kinugawa, K; Komuro, I; Momomura, SI; Okamoto, H; Saito, Y; Sakata, Y; Yamamoto, K; Yasumura, Y, 2017) |
| "The transdermal formulation of bisoprolol may be useful for the early introduction of β-blockers in patients admitted with cardiac symptoms associated with myocardial ischemia or heart failure." | 4.02 | An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms. ( Horiuchi, N; Kobayashi, T; Kobayashi, Y; Nakamura, S; Nakanishi, H; Naruhashi, K; Nozaki, A; Okugawa, H, 2021) |
| "Men with locally advanced or metastatic prostate cancer were randomly allocated (1:2 from August, 2007 then 1:1 from February, 2011) to either LHRHa according to local practice or tE2 patches (four 100 μg patches per 24 h, changed twice weekly, reducing to three patches twice weekly if castrate at 4 weeks [defined as testosterone ≤1·7 nmol/L])." | 3.01 | Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. ( Alhasso, A; Clarke, NW; Collins, GN; Deighan, JV; Dixit, S; Duong, T; Forcat, S; Gilbert, DC; Kockelbergh, R; Kynaston, H; Langley, RE; Laniado, ME; Macnair, A; Madaan, S; Manetta, C; Mangar, S; Marshall, J; McFarlane, J; Mckay, S; Muazzam, IA; Nankivell, M; Paez, E; Parmar, M; Pope, A; Robinson, A; Rosen, SD; Scrase, CD; Sundaram, SK; Weiss, M; Williams, ST; Worlding, J, 2021) |
| "However, orthostatic hypotension (OH) is sometimes caused by BBs." | 1.56 | Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T; Sano, T, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiuchi, S | 1 |
| Hisatake, S | 1 |
| Kabuki, T | 1 |
| Oka, T | 1 |
| Dobashi, S | 1 |
| Fujii, T | 1 |
| Sano, T | 1 |
| Ikeda, T | 1 |
| Nozaki, A | 1 |
| Kobayashi, T | 1 |
| Naruhashi, K | 1 |
| Okugawa, H | 1 |
| Horiuchi, N | 1 |
| Nakanishi, H | 1 |
| Kobayashi, Y | 1 |
| Nakamura, S | 1 |
| Langley, RE | 1 |
| Gilbert, DC | 1 |
| Duong, T | 1 |
| Clarke, NW | 1 |
| Nankivell, M | 1 |
| Rosen, SD | 1 |
| Mangar, S | 1 |
| Macnair, A | 1 |
| Sundaram, SK | 1 |
| Laniado, ME | 1 |
| Dixit, S | 1 |
| Madaan, S | 1 |
| Manetta, C | 1 |
| Pope, A | 1 |
| Scrase, CD | 1 |
| Mckay, S | 1 |
| Muazzam, IA | 1 |
| Collins, GN | 1 |
| Worlding, J | 1 |
| Williams, ST | 1 |
| Paez, E | 1 |
| Robinson, A | 1 |
| McFarlane, J | 1 |
| Deighan, JV | 1 |
| Marshall, J | 1 |
| Forcat, S | 1 |
| Weiss, M | 1 |
| Kockelbergh, R | 1 |
| Alhasso, A | 1 |
| Kynaston, H | 1 |
| Parmar, M | 1 |
| Momomura, SI | 1 |
| Saito, Y | 1 |
| Yasumura, Y | 1 |
| Yamamoto, K | 1 |
| Sakata, Y | 1 |
| Daimon, M | 1 |
| Kinugawa, K | 1 |
| Okamoto, H | 1 |
| Dohi, N | 1 |
| Komuro, I | 1 |
2 trials available for oxybutynin and Heart Failure
| Article | Year |
|---|---|
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
Topics: Acute Coronary Syndrome; Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Embolic Stro | 2021 |
Efficacy and Safety of Switching From Oral Bisoprolol to Transdermal Patch in Japanese Patients With Chronic Heart Failure.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Asian People; Bisoprolol; Chronic Disease; Fema | 2017 |
2 other studies available for oxybutynin and Heart Failure
| Article | Year |
|---|---|
Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Pressure; Female; Heart Failure; Humans; Hypert | 2020 |
An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms.
Topics: Acute Coronary Syndrome; Acute Disease; Administration, Cutaneous; Adrenergic beta-1 Receptor Antago | 2021 |